{"product_id":"nsj-v9366-20ug-20ug","title":"Recombinant OLIG2 Antibody, 20 ug","description":"\u003cp\u003eOlig2, a basic helix loop helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid\/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue.\u003c\/p\u003e\u003ch3\u003eSpecifications\u003c\/h3\u003e\u003ctable style=\"width:100%; border-collapse:collapse;\"\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eCatalog No\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eV9366-20UG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFamily\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePrimary antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eQty\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e20 ug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormulation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormat\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePurified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClone\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eOLIG2\/6695R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eHost Animal\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRabbit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClonality\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecombinant Rabbit Monoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eIsotype\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRabbit IgG, kappa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eSpecies Reactivity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eIHC-P\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Details\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eImmunohistochemistry (FFPE): 1-2ug\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Note\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eOptimal dilution of the recombinant OLIG2 antibody should be determined by the researcher.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLocalization\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eNucleus, Cytoplasm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eImmunogen\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eA portion of amino acids 200-300 was used as the immunogen for the recombinant OLIG2 antibody.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePurity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eProtein A\/G affinity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStorage\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAliquot the recombinant OLIG2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLimitation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eThis recombinant OLIG2 antibody is available for research use only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eUniprot #\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eQ13516\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStatus\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAvailable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePDF Link\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e\u003ca href=\"https:\/\/www.nsjbio.com\/tds-pdf\/recombinant-olig2-antibody-olig26695r-v9366\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps:\/\/www.nsjbio.com\/tds-pdf\/recombinant-olig2-antibody-olig26695r-v9366\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eTitle\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecombinant OLIG2 Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eDescription\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eOlig2, a basic helix loop helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid\/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"NSJ Bioreagents","offers":[{"title":"20 ug","offer_id":51544889950488,"sku":"V9366-20UG","price":259.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/get_image_24ed1c76-dcfa-45c1-9eff-d1354733797f.jpg?v=1768193672","url":"https:\/\/danabiosci.com\/products\/nsj-v9366-20ug-20ug","provider":"Dana Bioscience","version":"1.0","type":"link"}